This week in therapeutics




Licensing status

Publication and contact information

Ophthalmic disease


Angiopoietin 1 (ANG1; ANGPT1)

Mouse studies suggest ANG1 could help treat retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). In an oxygen-induced retinopathy mouse model of ROP and PDR, intravitreal injection of Ang1 decreased avascular area, vascular leakage and retinal neuron apoptosis compared with injection of Fc control and showed greater potency than Eylea aflibercept. Next steps could include testing Ang1 in additional animal models of retinal disease.
Regeneron Pharmaceuticals Inc., Bayer AG and Santen Pharmaceutical Co. Ltd. market Eylea, a human fusion protein that binds all forms of VEGF-A and placental growth factor (PGF; PlGF), to treat ocular disorders, including age-related macular degeneration (AMD), macular edema and retinal vein occlusion.

SciBX 6(40); doi:10.1038/scibx.2013.1138
Published online Oct. 17, 2013

Patent and licensing status unavailable

Lee, J. et al. Sci. Transl. Med.; published online Sept. 13, 2013;
Contact: Gou Young Koh, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
Contact: Ook-Joon Yoo, same affiliation as above